Review of the role of probiotics in gastrointestinal diseases in adults;Revisión del papel de los probióticos en la patología gastrointestinal del adulto

Gastroenterologia y Hepatologia

Volumn 40, Issue 6, 2017, Pages 417-429

  Sebastián Domingo, Juan José ^a  

^a HOSPITAL ROYO VILLANOVA   (Spain)

Author keywords

Bifidobacterium; Clostridium difficile; Colitis, Ulcerative; Constipation; Crohn disease; Diarrhea; Gastrointestinal diseases; Helicobacter pylori; Irritable bowel syndrome; Lactobacillus; Pouchitis; Probiotics

Indexed keywords

PROBIOTIC AGENT; CYTOKINE;

ACUTE DIARRHEA; ADULT; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DISEASE ERADICATION; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; ILEITIS; LANGUAGE; PRACTICE GUIDELINE; SHORT SURVEY; CLINICAL TRIAL (TOPIC); DIARRHEA; HELICOBACTER PYLORI; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; IRRITABLE COLON; SECRETION (PROCESS); TREATMENT OUTCOME;

ADULT; CLINICAL TRIALS AS TOPIC; CYTOKINES; DIARRHEA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROBIOTICS; TREATMENT OUTCOME;

EID: 85011578825     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2016.12.003     Document Type: Short Survey

References (94)

1. Penner, R., Fedorak, R.N., Madsen, K.L., Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol 5 (2005), 596–603.
2. Sullivan, Å., Nord, C.E., Probiotics and gastrointestinal diseases. J Intern Med 257 (2005), 78–92.
3. Girardin, M., Seidman, E.G., Indications for the use of probiotics in gastrointestinal diseases. Dig Dis 29 (2011), 574–587.
4. Sullivan, A., Nord, C.E., Probiotics and gastrointestinal diseases. J Intern Med. 257 (2005), 78–92.
5. Passariello, A., Agricole, P., Malfertheiner, P., A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin 30 (2014), 1055–1064.
6. Islam, S.U., Clinical uses of probiotics. Medicine (Baltimore)., 95, 2016, e2658.
7. Marteau, P., Living drugs for gastrointestinal diseases: the case for probiotics. Dig Dis 24:1-2 (2006), 137–147.
8. Bergonzelli, G.E., Blum, S., Brüssow, H., Corthésy-Theulaz, I., Probiotics as a treatment strategy for gastrointestinal diseases?. Digestion 72 (2005), 57–68.
9. Wasilewski, A., Zielińska, M., Storr, M., Fichna, J., Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm Bowel Dis 21 (2015), 1674–1682.
10. Issa, I., Moucari, R., Probiotics for antibiotic-associated diarrhea: do we have a verdict?. World J Gastroenterol 20 (2014), 17788–17795.
11. Allen, S.J., The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin North Am 29 (2015), 135–144.
12. Shojania, K.G., Bero, L.A., Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract. 4 (2001), 157–162.
13. Allen, S.J., Martinez, E.G., Gregorio, G.V., Dans, L.F., Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev., 2010 Nov 10, CD003048.
14. Rijkers, G.T., Bengmark, S., Enck, P., Haller, D., Herz, U., Kalliomaki, M., et al. Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr. 140 (2010), 671S–676S.
15. Preidis, G.A., Hill, C., Guerrant, R.L., Ramakrishna, B.S., Tannock, G.W., Versalovic, J., Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology. 140 (2011), 8–14.
16. Jafarnejad, S., Shab-Bidar, S., Speakman, J.R., Parastui, K., Daneshi-Maskooni, M., Djafarian, K., Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18-64 years) but not the elderly (>65 years): A meta-analysis. Nutr Clin Pract. 31 (2016), 502–513.
17. Hempel, S., Newberry, S.J., Maher, A.R., Wang, Z., Miles, J.N., Shanman, R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 307 (2012), 1959–1969.
18. Szajewska, H., Kołodziej, M., Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 42 (2015), 1149–1157.
19. Szajewska, H., Kołodziej, M., Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 42 (2015), 793–801.
20. Patro-Golab, B., Shamir, R., Szajewska, H., Yogurt for treating antibiotic-associated diarrhea: Systematic review and meta-analysis. Nutrition. 31 (2015), 796–800.
21. Goldenberg, J.Z., Ma, S.S., Saxton, J.D., Martzen, M.R., Vandvik, P.O., Thorlund, K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev., 2013, CD006095.
22. Johnston, B.C., Ma, S.S., Goldenberg, J.Z., Thorlund, K., Vandvik, P.O., Loeb, M., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med. 157 (2012 Dec 18), 878–888.
23. Lau, C.S., Chamberlain, R.S., Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 9 (2016), 27–37.
24. Maziade, P.J., Andriessen, J.A., Pereira, P., Currie, B., Goldstein, E.J., Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin. 29 (2013), 1341–1347.
25. Allen, S.J., Wareham, K., Wang, D., Bradley, C., Hutchings, H., Harris, W., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet., 382, 2013, 1249.
26. McFarland, L.V., Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 5 (2007), 97–105.
27. Takahashi, O., Noguchi, Y., Omata, F., Tokuda, Y., Fukui, T., Probiotics in the prevention of traveler's diarrhea: meta-analysis. J Clin Gastroenterol. 41 (2007), 336–337.
28. McLaughlin, S.D., Clark, S.K., Tekkis, P.P., Ciclitira, P.J., Nicholls, R.J., Review article: restorative proctocolectomy, indications, management of complications and follow-up–a guide for gastroenterologists. Aliment Pharmacol Ther 27 (2008), 895–909.
29. Turroni, S., Vitali, B., Candela, M., Gionchetti, P., Rizzello, F., Campieri, M., et al. Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. World J Gastroenterol 16 (2010), 30–41.
30. Shen, J., Zuo, Z.X., Mao, A.P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 20 (2014), 21–35.
31. Elahi, B., Nikfar, S., Derakhshani, S., Vafaie, M., Abdollahi, M., On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 53 (2008), 1278–1284.
32. Tomasz, B., Zoran, S., Jarosław, W., Ryszard, M., Marcin, G., Robert, B., et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. Biomed Res Int., 2014, 2014, 208064.
33. Persborn, M., Gerritsen, J., Wallon, C., Carlsson, A., Akkermans, L.M., Söderholm, J.D., The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther. 38 (2013), 772–783.
34. Holubar, S.D., Cima, R.R., Sandborn, W.J., Pardi, D.S., Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev., 2010, CD001176.
35. Ringel, Y., Carroll, I.M., Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 19 (2009), 141–150.
36. Salonen, A., de Vos, W.M., Palva, A., Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 156 (2010), 3205–3215.
37. Moayyedi, P., Ford, A.C., Talley, N.J., Cremonini, F., Foxx-Orenstein, A.E., Brandt, L.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 59 (2010), 325–332.
38. Brenner, D.M., Moeller, M.J., Chey, W.D., Schoenfeld, P.S., The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 104 (2009), 1033–1049.
39. Hoveyda, N., Heneghan, C., Mahtani, K.R., Perera, R., Roberts, N., Glasziou, P., A systematic review and metaanalysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol., 9, 2009, 15.
40. McFarland, L.V., Dublin, S., Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 14 (2008), 2650–2661.
41. Parkes, G.C., Sanderson, J.D., Whelan, K., Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 69 (2010), 187–194.
42. Ford, A.C., Quigley, E.M., Lacy, B.E., Lembo, A.J., Saito, Y.A., Schiller, L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 109 (2014), 1547–1561.
43. Ringel, Y., Ringel-Kulka, T., The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 45:Suppl (2011), S145–S148.
44. Lorenzo-Zúñiga, V., Llop, E., Suárez, C., Alvarez, B., Abreu, L., Espadaler, J., et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 20 (2014), 8709–8716.
45. Yoon, J.S., Sohn, W., Lee, O.Y., Lee, S.P., Lee, K.N., Jun, D.W., et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 29 (2014), 52–59.
46. McKenzie, Y.A., Thompson, J., Gulia, P., Lomer, M.C., et al., (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association). British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet., 2016 Jun 6. doi: 10.1111/jhn.
47. Begtrup, L.M., de Muckadell, O.B., Kjeldsen, J., Christensen, R.D., Jarbøl, D.E., Long-term treatment with probiotics in primary care patients with irritable bowel syndrome–a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol. 48 (2013), 1127–1135.
48. Whorwell, P.J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 101 (2006), 1581–1590.
49. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 128 (2005), 541–551.
50. Nobaek, S., Johansson, M.L., Molin, G., Ahrné, S., Jeppsson, B., Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 95 (2000), 1231–1238.
51. Saggioro, A., Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 38:6 Suppl (2004), S104–S106.
52. Carroll, I.M., Ringel-Kulka, T., Keku, T.O., Chang, Y.H., Packey, C.D., Sartor, R.B., et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 301 (2011), G799–G807.
53. Ortiz-Lucas, M., Tobías, A., Saz, P., Sebastián, J.J., Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig. 105 (2013), 19–36.
54. Ortiz Lucas, M., Tobías, A., Saz Peiró, P., Sebastián, J.J., Probiotics for specific treatment of pain in irritable bowel syndrome: a review. Rev Col Gastroenterol 29 (2014), 146–155.
55. Khalif, I.L., Quigley, E.M., Konovitch, E.A., Maximova, I.D., Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis 37 (2005), 838–849.
56. Quigley, E.M., Bacteria: a new player in gastrointestinal motility disorders–infections, bacterial overgrowth, and probiotics. Gastroenterol Clin North Am 36 (2007), 735–748.
57. Waller, P.A., Gopal, P.K., Leyer, G.J., Ouwehand, A.C., Reifer, C., Stewart, M.E., et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 46 (2011), 1057–1064.
58. Dimidi, E., Christodoulides, S., Fragkos, K.C., Scott, S.M., Whelan, K., The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 100 (2014), 1075–1084.
59. Chmielewska, A., Szajewska, H., Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol. 16 (2010), 69–75.
60. Gisbert, J.P., Calvet, X., Bermejo, F., Boixeda, D., Bory, F., Bujanda, L., et al. III Spanish Consensus Conference on Helicobacter pylori infection. Gastroenterol Hepatol. 36 (2013), 340–374.
61. Campillo A, Ostiz M, Amorena E, Kutz M, La Iglesia M, et al. Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection. Med Clin (Barc). 2016. pii: S0025-7753(16)30165-8.
62. Gisbert, J.P., Calvet, X., O'Connor, A., Mégraud, F., O'Morain, C.A., Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 44 (2010), 313–325.
63. Tong, J.L., Ran, Z.H., Shen, J., Zhang, C.X., Xiao, S.D., Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25 (2007), 155–168.
64. Dajani, A.I., Abu Hammour, A.M., Yang, D.H., Chung, P.C., Nounou, M.A., Yuan, K.Y., et al. Do probiotics improve eradication response to Helicobacter Pylori on standard triple or sequential therapy?. Saudi J Gastroenterol 19 (2013), 113–120.
65. Wilhelm, S.M., Johnson, J.L., Kale-Pradhan, P.B., Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 45:7-8 (2011), 960–966.
66. Zhang, M.M., Qian, W., Qin, Y.Y., He, J., Zhou, Y.H., Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 21 (2015), 4345–4357.
67. Ma, F., Zhou, C., Wang, J., Liu, T., Liu, J., Probiotics in the treatment of peptic ulcer infected by helicobacter pylory and its safety. Pak J Pharm Sci. 28:3 Suppl (2015), 1087–1090.
68. Zheng, X., Lyu, L., Mei, Z., Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 105 (2013), 445–453.
69. Dore, M.P., Goni, E., di Mario, F., Is there a role for probiotics in Helicobacter pylori therapy?. Gastroenterol Clin North Am 44 (2015), 565–575.
70. Mukai, T., Asasaka, T., Sato, E., Mori, K., Matsumoto, M., Ohori, H., Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 32 (2002), 105–110.
71. Dore, M.P., Soro, S., Rocchi, C., Loria, M.F., Bibbò, S., Pes, G.M., Inclusion of Lactobacillus Reuteri in the treatment of Helicobacter pylori in sardinian patients: A case report series. Medicine (Baltimore)., 95, 2016, e3411.
72. Holz, C., Busjahn, A., Mehling, H., Arya, S., Boettner, M., Habibi, H., et al. Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: A Pilot Study. Probiotics Antimicrob Proteins. 7 (2015), 91–100.
73. Szajewska, H., Horvath, A., Kołodziej, M., Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 41 (2015), 1237–1245.
74. Naidoo, K., Gordon, M., Fagbemi, A.O., Thomas, A.G., Akobeng, A.K., Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev., 2011, CD007443.
75. Do, V.T., Baird, B.G., Kockler, D.R., Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother. 44 (2010), 565–571.
76. Zocco, M.A., dal Verme, L.Z., Cremonini, F., Piscaglia, A.C., Nista, E.C., Candelli, M., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 23 (2006), 1567–1574.
77. Derikx, L.A., Dieleman, L.A., Hoentjen, F., Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 30 (2016), 55–71.
78. Chibbar, R., Dieleman, L.A., Probiotics in the management of ulcerative colitis. J Clin Gastroenterol 49:Suppl 1 (2015), S50–S55.
79. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45 Suppl:S139-44.
80. Floch, M.H., Walker, W.A., Sanders, M.E., Nieuwdorp, M., Kim, A., Brenner, D.A., et al. Recommendations for Probiotic Use–2015 Update: proceedings and consensus opinion. J Clin Gastroenterol 49:Suppl 1 (2015), S69–S73.
81. Kruis, W., Fric, P., Pokrotnieks, J., Lukás, M., Fixa, B., Kascák, M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 53 (2004), 1617–1623.
82. Jonkers, D., Penders, J., Masclee, A., Pierik, M., Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 72 (2012), 803–823.
83. Mardini, H.E., Grigorian, A.Y., Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis. 20 (2014), 1562–1567.
84. Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G.M., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 105 (2010), 2218–2227.
85. Prantera, C., Scribano, M.L., Falasco, G., Andreoli, A., Luzi, C., Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 51 (2002), 405–409.
86. Schultz, M., Timmer, A., Herfarth, H.H., Sartor, R.B., Vanderhoof, J.A., Rath, H.C., Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 4 (2004), 1–5.
87. Marteau, P., Lémann, M., Seksik, P., Laharie, D., Colombel, J.F., Bouhnik, Y., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 55 (2006), 842–847.
88. Malchow, H.A., Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?. J Clin Gastroenterol. 25 (1997), 653–658.
89. Guslandi, M., Role of probiotics in Crohn's disease and in pouchitis. J Clin Gastroenterol 49:Suppl 1 (2015), S46–S49.
90. Butterworth, A.D., Thomas, A.G., Akobeng, A.K., Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev., 2008, CD006634.
91. Rolfe, V.E., Fortun, P.J., Hawkey, C.J., Bath-Hextall, F., Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev., 2006, CD004826.
92. Guslandi, M., Mezzi, G., Sorghi, M., Testoni, P.A., Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 45 (2000), 1462–1464.
93. Bourreille, A., Cadiot, G., le Dreau, G., Laharie, D., Beaugerie, L., Dupas, J.L., et al., FLORABEST Study Group. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 11 (2013), 982–987.
94. Lichtenstein, L., Avni-Biron, I., Ben-Bassat, O., Probiotics and prebiotics in Crohn's disease therapies. Best Pract Res Clin Gastroenterol. 30 (2016), 81–88.